Clinical Research Directory

Inclusion Criteria: * Patients are aged 18 years old or older with a diagnosis of symptomatic myeloma, * Stable clinical status as deemed by responsible investigator, * Personally (or caregiver) willing and deemed capable to self-administer with teaching, * Previously received more than 4 injections of bortezomib within the hospital and/or cancer centre environment, * Signed informed consent. Exclusion Criteria: * Currently participating in clinical trials that includes the use of bortezomib, * History of allergic reactions to bortezomib, * History of bleeding attributable to bortezomib, * History of greater than or equal to grade 3 side effects attributable to bortezomib, * Clinically deemed unlikely to be compliant with therapy by responsible investigator, * Life expectancy anticipated to be less than 6 months, * Deemed geographically inaccessible to receive care.